1-6 of 6
ponatinib
Close
Sort by
Journal Articles

Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N -acetylcysteine

Clinical Trials & Observations
Melinda D. Wu, James Hodovan, Kris Kumar, Bart Moulton, Sven Olson, Aubre Gilbert, Matthew D. Wood, Jonathan R. Lindner
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4083–4085.
https://doi.org/10.1182/bloodadvances.2020002644
Published: 2020
Includes: Supplemental data
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data
Journal Articles

Poor tolerability to ponatinib in Indian CML patients

Clinical Trials & Observations
Charanpreet Singh, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Dinesh Bhurani, Rayaz Ahmed, Narendra Agrawal, Jose Easow, Neelam Varma, Pankaj Malhotra
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1927–1929.
https://doi.org/10.1182/bloodadvances.2020001944
Published: 2020
Journal Articles

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia

Clinical Trials & Observations
Onyee Chan, Chetasi Talati, Leidy Isenalumhe, Samantha Shams, Lisa Nodzon, Michael Fradley, Kendra Sweet, Javier Pinilla-Ibarz
Journal: Blood Advances
Blood Adv (2020) 4 (3): 530–538.
https://doi.org/10.1182/bloodadvances.2019000268
Published: 2020
Journal Articles

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets

Alona Merkulova, Steven C. Mitchell, Evi X. Stavrou, Gabriel L. Forbes, Alvin H. Schmaier
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2312–2316.
https://doi.org/10.1182/bloodadvances.2019000034
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data